Fucosylated α(1)-acid glycoprotein as a biomarker to predict prognosis following tumor immunotherapy of patients with lung cancer

Immunotherapy targeting immune checkpoint molecules has provided remarkable clinical benefits in cancer patients but no clinically relevant biomarker for predicting treatment outcomes exists. Recently, we demonstrated that glycan structures of serum α(1)-acid glycoprotein (AGP) changed dramatically...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokobori, Takehiko, Yazawa, Shin, Asao, Takayuki, Nakazawa, Nobuhiro, Mogi, Akira, Sano, Rie, Kuwano, Hiroyuki, Kaira, Kyoichi, Shirabe, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787216/
https://www.ncbi.nlm.nih.gov/pubmed/31601857
http://dx.doi.org/10.1038/s41598-019-51021-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787216/
https://www.ncbi.nlm.nih.gov/pubmed/31601857
http://dx.doi.org/10.1038/s41598-019-51021-2

Ejemplares similares